Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.26M | 26.55M | 1.75M | 1.65M | 1.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.26M | 26.55M | 1.75M | 1.65M | 1.13M |
| Cost of Revenue | 1.60M | 25.93M | 25.85M | 17.81M | 1.63M |
| Gross Profit | -342.00K | 621.00K | -24.10M | -16.16M | -495.00K |
| SG&A Expenses | 11.61M | 21.06M | 39.59M | 39.19M | 32.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.94M | 46.99M | 65.44M | 57.00M | 46.46M |
| Operating Income | -25.68M | -20.44M | -63.69M | -55.35M | -45.33M |
| Income Before Tax | -25.30M | -33.77M | -64.81M | -53.43M | -48.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.30M | -33.77M | -64.81M | -53.43M | -48.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.30M | -33.77M | -64.81M | -53.43M | -48.40M |
| EBIT | -25.68M | -20.44M | -63.69M | -55.35M | -45.33M |
| EBITDA | -25.50M | -20.31M | -63.57M | -55.22M | -45.19M |
| EPS Basic | -0.07 | -0.09 | -0.18 | -0.17 | -0.20 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.11 | -0.11 | -0.12 |
| EPS Diluted | -0.07 | -0.09 | -0.18 | -0.17 | -0.20 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.11 | -0.11 | -0.12 |
| Average Basic Shares Outstanding | 362.07M | 361.49M | 361.49M | 310.84M | 245.39M |
| Average Diluted Shares Outstanding | 362.07M | 361.49M | 361.49M | 310.84M | 245.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |